Section
This analysis reveals that TERT promoter mutations, increasingly prevalent with age, better predict poor outcomes in papillary thyroid carcinoma than age alone, offering enhanced risk stratification for clinical management.
This prospective study reveals that health-related quality of life (HR-QoL) declines immediately after hepatectomy for high-risk colorectal liver metastases but returns to or surpasses baseline by one year in patients without recurrence, un
This article analyzes 40-year trends in incidence, mortality, and survival of endometrial, ovarian, and cervical cancers among Nordic women aged 0-49, highlighting evolving epidemiology and implications for age-specific prevention.
This review contrasts early- and late-phase gynecologic oncology trials, underscoring disparities in trial completion, publication, and racial/ethnic minority enrollment, highlighting the need to improve inclusivity and reporting.
Distinct gut microbial profiles but shared metabolomic markers, especially fecal acetate, predict response and survival with combination immunotherapy in metabolic dysfunction-associated and viral hepatitis-related hepatocellular carcinoma.
PCK1 deficiency in hepatocytes drives metabolic reprogramming that fosters MASH-HCC progression by inducing CD8+ T cell dysfunction through 12-HETE-p38 signaling, highlighting a metabolic immunotherapy target to enhance anti-PD-1 efficacy.
This study quantifies how federal and industry sponsorship differ in US cancer clinical trials, highlighting complementary focuses: industry emphasizes single-agent drug therapies, while federal trials prioritize multimodality regimens, rar
A phase 2 trial shows pembrolizumab combined with low-dose quad-shot radiotherapy yields encouraging response rates and survival outcomes in recurrent, unresectable head and neck squamous cell carcinoma.
A large randomized clinical trial demonstrated that preoperative high-dose corticosteroids do not reduce major postoperative complications in elective digestive cancer surgery, challenging their routine use for perioperative inflammation co
Multisociety 2026 guidance clarifies diagnosis and management of atypical breast lesions and lobular carcinoma in situ, balancing excision, surveillance, and chemoprevention based on lesion type, radiologic concordance, and risk.
This article examines the incidence and management of intraoperative adverse events during robot-assisted minimally invasive esophagectomy, highlighting their impact on surgical results and postoperative recovery.
This study analyzes surgical specimens from the SANO trial, revealing that local regrowth after neoadjuvant chemoradiotherapy predominantly involves mucosa and submucosa and supports endoscopic monitoring in active surveillance, with surger
A pilot program using former gynecologic oncology trial participants as patient ambassadors improved confidence and perceptions about clinical trials among trial-naïve patients, highlighting a feasible peer-education approach.
The OPAL phase 2 trial compared neoadjuvant niraparib to standard platinum-taxane chemotherapy in newly diagnosed HR-deficient advanced ovarian cancer, showing inferior response rates with niraparib and a safety profile consistent with PARP
This analysis of nearly 1.4 million U.S. gynecologic cancer cases reveals that racial/ethnic minorities, socially vulnerable communities, and women lacking geographic access to gynecologic oncologists face higher odds of late-stage cancer d
This study delineates three unique molecular subtypes of cholangiocarcinoma via integrated multiomic and machine learning methodologies, highlighting TNK1 kinase as a promising targeted therapy in a metabolic subtype.
Between 2010 and 2023 in Denmark, meningioma incidence doubled while treatment rates remained steady. Extensive follow-up imaging was common but rarely altered management, highlighting opportunities for risk-adapted surveillance protocols.
A nationwide prospective study identifies early fatigue and poor mental health as key predictors of long-term fatigue in differentiated thyroid cancer patients, while thyrotropin suppression shows no association with fatigue.
This study compares US federally sponsored and industry-sponsored cancer clinical trials, highlighting differences in trial focus, populations, and interventions, and underscoring their complementary roles in advancing oncology research.
NSUN6 deficiency in pancreatic cancer promotes immune suppression by enhancing immunosuppressive macrophage infiltration via the KDM5A-CCL2 axis, leading to resistance to immune checkpoint blockade; targeting this pathway offers a promising
